Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
MarketWatch news may prevent that from happening.
Low Credit Ratings Prevent Bond Insurers From a Rebound
http://www.marketwatch.com/story/low-credit-ratings-prevent-bond-insurers-from-a-rebound-2010-11-04?siteid=nbsh
This may be the reason for this PM activity...
Refinancing Surge Gives Lift to Banks Amid Foreclosure Scrutiny
http://www.bloomberg.com/news/2010-10-25/refinancing-surge-gives-lift-to-banks-amid-foreclosure-scrutiny.html
Thank you, Matt.
Thanks! it looks like volume may be a little weaker now. IMO
Matt, do you still think GBE will hit $1.47 this week? TIA
Can you put me down for MIHI ? thanks.
Matt, please go 'light' on those posts that could keep us busy for 'years'... some of us don't have many years left!! ROFL
Thank you, Sir! I was trying to see if you just lowered the blue support line a little to include this dip. That would still leave this as an uptrend line. IMO But I also noticed the RSI moving down and MACD lines could converge later.
Matt, SIRI dipped below your blue support line. Do you consider exiting this now? TIA
Then if this is your DD (this remembrance of Dr Seymour) why are you even here (holding a position in NNVC)? His name has been on almost every thing I've ever read concerning NNVC so it could hardly have been missed for the last couple of years.
Petekoz1, my post was not directed at you. It was meant for Ovidius but has probably fallen on deaf ears there. Some investors/traders don't belong in penny stocks. Public reply is due to the fact that I'm not a premium member here. GLTA
For some reason, you didn't do very good DD on your stock position. And now, you want to sit back and point the finger at others because you didn't follow a reliable investment strategy or you've just relied on others' posts for your investment decisions. Now who's the lazy one?
First the bashers complain that when they supposedly call, all they got was an answering machine. Now, again supposedly all Corporate does, is sit around answering emails and such. Why not just cut your losses and move on. Plain and simple.
If you can't stand the heat, get out of the fire. Cut your losses and move on - instead of posting crap. IMO
Sooner or later those MM's are going to run out of their 'pocket' shares again and need to purchase more. Then the SP should advance pretty good. IMO )
GLTA
I agree, Nano. I copied that news article directly from Marketwatch. The CBS affiliate in Baton Rouge would have been Channel 9. )
At least our local bashers can't consider this 'just another hohum monday am' pump. LOL
NanoViricides, Inc. Herpes Study Results Discussed on CBS News Report
WEST HAVEN, Conn., Aug 12, 2009 (BUSINESS WIRE) -- NanoViricides, Inc. (OTC BB: NNVC.OB) (the "Company"), reported today that the CBS affiliate TV station WBRZ interviewed Professor K. Gus Kousoulas , PhD, in which he explained the potential implications of the Company's nanoviricides(TM) anti-Herpes drug candidates.
"Over 90% of the people are infected with Herpes, whether they know it or not," said Dr. Kousoulas, adding "it can manifest as cold sores or genital herpes. [These manifestations] can be very painful, especially for women." He also commented that "Unlike true love, herpes is forever," referring to the fact that the herpes virus goes dormant in the body between recurrent manifestations, and that there is at present no cure for herpes.
"A nanoviricide drug could be an important breakthrough," he said, explaining, "the duration of a cold sore could be reduced drastically, from a month to just a few days [by applying a nanoviricide skin cream]," based on studies conducted in the laboratories at the Louisiana State University's (LSU) Division of Biotechnology and Molecular Medicine (BIOMMED). In cell culture testing, his laboratory found that certain nanoviricides eliminated 99.99% of the virus from infected cells.
A video excerpt of the interview can be found at 2theadvocate.com | News | Possible progress in herpes treatment -- Baton Rouge, LA. The video was also linked to the front page of The Drudge Report, DRUDGE REPORT 2009(R).
The LSU School of Veterinary Medicine has received a grant of $11.1M in July 2009, adding to a previous award of $9.9M in 2004, for the LSU Center of Biomedical Research Excellence (COBRE) from the National Institutes of Health (NIH). Konstantin G. Kousoulas, PhD, Professor of Veterinary Virology and Director of BIOMMED, is the administrator of the COBRE program at the LSU School of Veterinary Medicine. He is also the Mary Louise Martin Professor of Virology and the Director of LSU-Tulane Center for Experimental Infectious Disease Research.
http://www.shortsqueeze.com/?symbol=nnvc&submit=Short+Quote%99
Here's another website that may be of interest:
http://www.otcbb.com/asp/tradeact_mv.asp?SearchBy=issue&Issue=nnvc&Month=6-1-2008&IMAGE1.x=0&IMAGE1.y=0
Absolutely!! The process is slow but I'm still here for the long haul.
As Trendy reported earlier:
NanoViricides, Inc. CEO Invited to Speak at NanoBio 2009 Conference
WEST HAVEN, Conn., Jun 22, 2009 (BUSINESS WIRE) -- NanoViricides, Inc. (OTC BB: NNVC.OB) (the "Company"), announced today that its CEO, Dr. Eugene Seymour, has been invited to present a talk, and, in addition, participate in presenting a workshop on "Nanoparticle Formulation: principles and applications", at the 3rd International Congress of NanoBiotechnology & NanoMedicine (NanoBio 2009) to be held in San Francisco on June 22-24, 2009. The website for the event is http://www.ianano.org. The conference is sponsored by, among others, The National Cancer Institute, the National Institute of Standards and Technology, the Lawrence Berkeley National Laboratory and Stanford University.
Dr Seymour plans to discuss the nature of the Company's nanoviricide(TM) drug technology and platform as well as results of various laboratory and animal studies against different viruses. Dr. Seymour will summarize the Company's successes against multiple types of influenza viruses including different H5N1 bird flu viruses and H1N1 virus similar to the current pandemic-causing H1N1. He will also talk about the Company's successes against HIV, adenoviral epidemic keratoconjunctivitis (EKC), Ebola and Rabies. In addition to these programs, the Company is also developing nanoviricide drugs against dengue viruses. His talk is scheduled for Tuesday, the 23rd June, 2009. The workshop takes place in two sessions on Monday, the 22nd.
NanoViricides, Inc. Eye Drug Testing Has Begun
Expanded Testing under a Material Transfer Agreement with a Pharma Company
WEST HAVEN, Conn., Jun 15, 2009 (BUSINESS WIRE) -- NanoViricides, Inc. (OTC BB: NNVC.OB) (the "Company"), reported today that testing of its topical eye drops drug candidate has begun at two different, independent facilities.
Testing of this broad-spectrum, topical, eye drug candidate by a major pharmaceutical company ("Party") is now in progress. The Company had previously announced in March that it had signed a Material Transfer Agreement with this Party. In addition, the Company is also evaluating this drug candidate against herpes keratitis of the eye at Thevac, LLC, a spin-off of the Louisiana State University (Study Director, K. G. Kousoulas, PhD).
The testing at the two facilities will independently evaluate performance of this drug candidate against several types and strains of many different viruses that cause keratitis or conjunctivitis of the eye. Cell culture studies as well as animal studies with different animal models have been planned.
"Execution of the material transfer agreement (MTA) is a step towards a potential licensing agreement," said Eugene Seymour, MD, MPH, CEO of Nanoviricides, Inc. The terms of the agreement do not allow the disclosure of the identity of the Party or the exact terms of the MTA.
HSV and some adenoviruses cause most of the cases of keratitis, a serious infection of the cornea. Importantly, HSV infection can lead to corneal scarring that may necessitate corneal transplantation. In addition, some adenoviruses cause a majority of conjunctivitis cases ("pink eye"). The remaining cases of conjunctivitis, caused by bacteria, are treatable with topical antibiotics. Currently, there are no effective treatments for viral diseases of the exterior portion of the eye.
The Company has already demonstrated strong efficacy against an adenovirus-caused external eye disease called epidemic kerato-conjunctivitis (EKC). Rapid clinical improvement in the treated animals was reported by independent researchers who tested the effects of the nanoviricides drug candidate against adenoviral EKC. Based on computer modeling, the Company believes that the broad-spectrum nature of the ligand used in this nanoviricide should enable it to be effective against HSV.
The total market for all forms of viral conjunctivitis/keratitis is estimated to be in the billions of dollars. The incidence of severe herpes (HSV) keratitis is estimated to be 250,000 cases per year in the USA. In Japan, where EKC is a reportable disease, it is estimated that there are at least one million cases per year. The number of cases of non-specific conjunctivitis (pink eye) is considered to be far greater, possibly into tens of millions in the US, and into hundreds of millions worldwide.
NNVC: NSLIJ Scientists to Present EKC-Cide(TM) Study Results at the GTC-Bio Conference on Ocular Diseases and Drug Discovery
http://www.marketwatch.com/News/Story/Story.aspx?guid={6FC26692-5094-4223-89D9-528034E92F92}&siteid=nbsh
South African Clinic Helps AIDS Patients Have Healthy Babies
http://www.foxnews.com/story/0,2933,459388,00.html
Thank you Trendy for the excellent analysis. GLTA
Try backing up your posts with links so we can "try" to believe you. LOL
What do you mean?
Got beef?
Unless a deal, etc is announced, we may see the "next" foot fall in this market crisis soon. Makes no difference to me - I'm still holding all my shares.
New crisis in commercial real estate looms
Malls, hotels may foreclose and banks can’t renegotiate loan terms
http://www.msnbc.msn.com/id/27928745/
Yahoo is not a good source for financials, news, etc. There are better sources for reliable numbers. IMO
Experts: HIV could be eliminated in a decade
http://www.usatoday.com/news/health/2008-11-26-hiv-world_N.htm?csp=34
If our fearless government can bail out Citigroup and we finally get a President in the White House who can actually make Mai Tais, ANYTHING is possible! LOL
I don't know about that - general market is up ~ 4% yet NNVC is up over 40% from Friday's close. There may be more to it than that.
Nano, did you misspell lass? LOL
Did you hear that last year when the SP was heading up? Same OLD psycho babble - different day. Can't you take a hint from anyone?
My thoughts - exactly!! A while back, he and his pet poodles over on Yahoo were going to start up their own website/board to bash NNVC. I guess they couldn't get anyone to listen to them there either. LOL
Nano, please let's keep politics out of this. LOL The last 7 3/4 years performance has definitely turned taken its toll on almost every phase of our economy including NNVC. Deals, studies, etc will take longer than anticipated. Major pharmaceuticals will think take much longer in their decisions about all aspects of business if they're smart.
And once again, your point is??
Dain, did you try under both symbols?